Validation that the CF33 platform is working just like it did on rodents.Well that's my take on this licenses allogeneic Car T cell therapy.There is a bit involved in this deal, not just the money and shares.Precision is happy to accept payment in the form of convertible.notes, that shows plenty of confidence in what IMU are offeringin the form of IP it has.Yes, the cap raise and dilution is a downer, and no one really seen!this coming, especially not me. At first I was not shore about the holething, but with further digging I'm absolutely thrilled with this deal.The strategy here is brilliant. Getting a Car T that can now go strait intoa registrational trail. IMU can partner with other big pharma Car T'sand also have their own Car T to go on with, this could be game changingwhen you think about it. We should have all seen something like thiscoming, there were enough hints a the latest presentations'.Another plus is that the Car T is allogenic, hence my opinion it couldbe a big game changer, it all points to an off the shelf cancer treatmentthat will be a lot cheaper than anything else out there.This now becomes a complete package for a company take over orlicencing to a major big pharma. Also, and of course is the elephantin the room, the manufacturing facility. 50 employes already to goand the size of it indicates there is plenty of confidence with in theIMU team., the factory has already got FDA approval,they know what the data is showing and they know whatthey have. Why else would you do a deal like this, they are sure nowbecause its working in humans just like they were anticipating.Big Pharma always seem to hold the cards, but when IMU present to theworld what they really have, it will be IMU holding the cards in myopinion.I can only go back to the last time I had a chat with Dr Yuman Fong afew mouths back, he wanted to tell me and my friend so much morebut he could not for obvious reasons, but he did say all in good timewe could be looking at a cure for cancer and wouldn't that bejust marvelous for all.There is nothing that I have said that others have not already, butfor me and my investment in IMU, I'm very, very happy with wherethey are heading and this latest development gives me more confidencethat we are on a big winner .This is just my opinion and not financial advice.
- Forums
- ASX - By Stock
- IMU
- Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-420
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.2M |
Open | High | Low | Value | Volume |
5.2¢ | 5.2¢ | 5.0¢ | $1.098M | 21.50M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
97 | 7481668 | 5.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.1¢ | 1703097 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
97 | 7481668 | 0.050 |
26 | 3019321 | 0.049 |
24 | 1822995 | 0.048 |
10 | 2942679 | 0.047 |
15 | 1604916 | 0.046 |
Price($) | Vol. | No. |
---|---|---|
0.051 | 1703097 | 4 |
0.052 | 4137566 | 15 |
0.053 | 2218416 | 9 |
0.054 | 1549915 | 8 |
0.055 | 1499783 | 10 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online